Choose Up the Items: Invivyd Engineers New COVID-19 Monoclonal Candidate

By Alex Philippidis

Practically two years after the Omicron variant bested the lead candidate of its predecessor firm, Adagio—inflicting its inventory to plunge 79%, its founding CEO to resign, and the corporate to rebrand—Invivyd has picked up the items with a brand new pipeline anchor, a monoclonal antibody (mAb) for stopping COVID-19 derived from the one which failed.

VYD222 is a re-engineered mAb that differs from the failed ADG20, now referred to as adintrevimab, by eight totally different amino acids. That enables VYD222 to shift barely the place it binds with the spike protein of SARS-CoV-2—a change that Invivyd causes will make the antibody a lot better in a position than adintrevimab at stopping symptomatic COVID-19 because the virus quickly evolves, forming new variants.

The re-engineering that wrought VYD222 displays a change in technique since Adagio grew to become Invivyd, towards creating a steady repertoire of SARS-CoV-2 neutralizing mAbs.

“We’ve actually shifted this thesis from a singular antibody that might be designed, developed, and assumed to have ongoing exercise, to at least one the place we search to satisfy viral evolution and the pace of viral evolution that we’ve seen in SARS-CoV-2,” Invivyd CEO Dave Hering informed GEN Edge. “We have to do that repeatedly. We’d like to have the ability to present antibodies on a daily up to date foundation that meet the brand new variants.”

In September, Invivyd dosed its first affected person within the Part III CANOPY pivotal trial (NCT06039449), designed to evaluate VYD222’s potential to guard in opposition to symptomatic COVID-19 at a 4,500 mg dose.

The trial will consider some 750 members in two cohorts: One in every of about 300 considerably immunocompromised members, the opposite about 450 members prone to publicity to SARS-CoV-2, randomized 2:1 to VYD222 or placebo. The first endpoint for Cohort A is serum neutralizing titers in opposition to related SARS-CoV-2 variants at Day 28. For Cohort B, the first endpoint is security and tolerability.

Buyers responded with a mini-surge that despatched Invivyd’s inventory value up 7%, from $1.77 a day earlier than the announcement to $1.89 a day after. Since then, the inventory has fallen 20%, closing at $1.51 on Monday.

Nonetheless, Michael J. Yee, fairness analyst with Jefferies, took a extra constructive view of the corporate over the summer season, giving Invivyd excessive marks for its pivotal examine design.

“We expect the Part III design is wise and aligned with FDA, which is able to permit them to shortly enroll the wanted [patients] for the minimally adequate 28 days titer stage information and ‘all-comer’ security information, whereas leveraging scientific information from the earlier adintrevimab as a prototype drug, to place collectively a complete information package deal for a possible EUA in a well timed trend,” Yee wrote in August.

Potential EUA submitting

Preliminary main endpoint information is anticipated to be launched by the tip of 2023 or early within the first quarter of 2024. Invivyd hopes that information will probably be constructive sufficient to help a possible emergency use authorization (EUA) submitting for VYD222, primarily based on what the corporate calls its “normal alignment” with an FDA regulatory pathway for that and anticipated follow-on mAb candidates.

Invivyd is just not disclosing what number of sufferers have since joined the preliminary participant in CANOPY, although Hering stated the trial goes as deliberate, and is inspired by what he referred to as “a good quantity of outreach” to the corporate’s investor relations from sufferers all in favour of becoming a member of the examine.

“Apparently, even individuals not immunocompromised have been fairly all in favour of enrolling within the trial. I attribute that to, amongst different issues, the truth that persons are nonetheless seeing COVID-19 circumstances of their communities and of their circles,” Hering stated.

Over the summer season, Invivyd stated VYD222 generated constructive preliminary information in its ongoing Part I trial (NCT05791318) displaying {that a} single administration of VYD222 was usually well-tolerated in any respect three dose ranges examined with no critical adversarial occasions. All dose ranges examined confirmed sturdy neutralization exercise in opposition to Omicron XBB.1.5 at Day 7.

“Given the dose-dependent robust 7-day titer information proven in Part I earlier, we expect the Part III might simply replicate Part I with stronger powering testing solely the best Part I IV [intravenous] dose of 4500 mg,” Yee noticed. “The titer ranges might come down a bit going from Day 7 to Day 28, however the 4500 mg dose confirmed large titer ranges as much as 16,800 or a ~121-fold improve in titer stage vs baseline in Part I which leaves sufficient ‘buffer’ and we should always nonetheless see a robust impact at this readout.”

“In an optimum state of affairs, IVVD might be launching beneath EUA for immuno-compromised [patients] within the label—and have income are available as quickly because the second half of 2024, Yee predicted, whereas sustaining his agency’s “Maintain” ranking and 12-month value goal of $1.50.

Multi-billion-dollar market

If that occurs, he added, VYD222 might share a multi-billion greenback marketplace for COVID-19-preventing antibodies with AstraZeneca, which is finding out its next-generation long-acting antibody (LAAB) AZD3152 within the Part II/III SUPERNOVA trial (NCT05648110).

Derived from B-cells donated by convalescent sufferers after SARS-CoV-2 an infection, AZD3152 is optimized with a half-life extension and decreased Fc effector perform and complement C1q binding platform anticipated to confer safety from COVID-19 for six months. An analogous platform was utilized by Evusheld (tixagevimab and cilgavimab), AstraZeneca’s COVID-19 antibody mixture which gained EUA final yr, then misplaced authorization in January because of lack of effectiveness in opposition to newer variants. AstraZeneca has stated it might make AZD3153 obtainable by yr’s finish by way of EUA, if information from the trial proves constructive.

Hering stated the marketplace for VYD222 is massive sufficient, relying on how immunocompromised is quantified and categorised, to vary from 8 to 18 million individuals. “We began, as you possibly can think about, doing work to look into the totally different populations that make up immunocompromised organ transplant sufferers: Folks with totally different oncology and cancers, particularly blood cancers. Folks on immune suppressants for rheumatoid arthritis, or a number of sclerosis dialysis,” Hering stated.

Though not technically thought-about immunocompromised, he famous, older adults develop issues with their immune programs: “You could possibly additionally see in a few of these populations a necessity for added merchandise past vaccines.”

“There’s an enormous unmet want particularly, in these populations we’ve been speaking about, and an actual must complement the medication cupboard with merchandise like ours,” Hering stated. “So, we’ve been working with regulators on how to do that effectively and the way to do that on an ongoing foundation, actually, with that purpose in thoughts.”

Invivyd was launched as Adagio Therapeutics, a spinout of Adimab, on the peak of the COVID-19 pandemic in 2020. After elevating $130 million in two financing rounds, Adagio initially sought to develop ADG2, an engineered antibody that efficiently provided full safety in opposition to extreme SARS-CoV-2 and SARS-CoV in mouse fashions.

By December 2020, Adagio had shifted its focus to adintrevimab, a more recent model of ADG2 that was engineered to supply an extended period of safety by extending the antibody’s serum half-life.

The brand new antibody, then referred to as ADG20, confirmed promise in opposition to not solely COVID-19 but additionally different coronaviruses, together with SARS-CoV-1 (SARS-CoV) and MERS. “Our view was, it’s nice to have a therapy for this specific outbreak, however why not purpose a bit of bit increased and determine a method of discovering antibodies that neutralize your complete clade of coronaviruses that focus on human ACE2?” Adagio co-founder and CEO Tillman Gerngross, PhD, informed GEN Edge in 2020, referring to angiotensin-converting enzyme 2.

By February 2021, Adagio took adintrevimab into the clinic, dosing the primary affected person in a Part I trial, and quickly advancing the mAb into two late-phase research, the Part III EVADE trial (NCT04859517) assessing the antibody’s prevention of COVID-19; and the Part II/III STAMP trial (NCT04805671), evaluating ADG20 as a therapy for COVID-19.

Hitting turbulence

Adagio hit turbulence in December 2021, when the corporate acknowledged that ADG20 had didn’t successfully neutralize the Omicron variant of SARS-CoV-2 (B1.1.529) in lab testing as the corporate had publicly predicted a month earlier. After outcomes failed to satisfy Adagio’s rosy prediction, which had despatched shares close to doubling, buyers punished the corporate severely, sending its shares cratering 79% in a single day to $7.26 from $34.26.

Two months later in February 2022, Gerngross resigned. He was succeeded by Hering, who had joined Adagio seven months earlier as COO. In September 2022, Adagio rebranded as Invivyd, a reputation supposed to replicate the corporate’s enterprise focus of making use of its discovery platform to develop and commercialize antibodies that transcend the boundaries of the human immune system to higher forestall and deal with infectious respiratory viral ailments, beginning with COVID-19.

Invivyd re-engineered adintrevimab into VYD222 utilizing its built-in discovery platform:

• First, monitor viral evolution and map widespread mutational escape routes to foretell future variants of concern.
• Use deep B-cell mining capabilities licensed from Adimab to isolate broadly neutralizing antibodies that focus on uncommon viral epitopes that aren’t beneath robust immune stress, thus growing the likelihood of sustained utility.
• Engineer antibodies to enhance their efficiency, breadth, biophysical properties, and developability. Utilizing affinity maturation, Invivyd can engineer candidates to have excessive exercise in opposition to particular viral variants it identifies as potential future variants of concern.

“When the omicron mutations occurred and decreased exercise, this engineering re-established these bindings and recreated the exercise and the binding. That has been actually helpful for a few causes,” Hering stated.

First, the re-engineering allowed Invivyd to use a brand new regulatory framework for its Part III trial permitting “immunobridging” by means of using information from serum-neutralizing titers in addition to beforehand generated scientific trial information from a prototype mAb—on this case, adintrevimab (ADG20).

Second, adintrevimab met the FDA’s three standards for a prototype mAb—it was initially established as a mAb; it accomplished pivotal, double-blind scientific trials; and it makes use of the identical manufacturing platform and has exercise in opposition to new present circulating variants, which VYD222 has proven. Adintrevimab stays inside Invivyd’s pipeline, with trials having concluded and a package deal of information able to submit for an EUA submitting depending on variant susceptibility: “If the virus mutates in a method that generates exercise for ADG20, we nonetheless have stock of the product.”

Adintrevimab and VYD222 are the one two named candidates listed in Invivyd’s pipeline. The corporate has three different COVID-19 mAb candidates, recognized solely as #3, #4, and #5, in discovery and preclinical phases—plus a mAb mixture candidate for prevention of influenza, within the early discovery part.

As new variants emerge, Hering stated, Invivyd envisions creating a number of new antibodies in response. “Our strategy is to take a look at a set of, mainly, a household of various antibodies. VYD222 comes from this ADG20 lineage. We do see that ‘222 may be re-engineered additional,” Hering stated.

Zigging and zagging

“We’ve achieved a few of that work already it versus the present variants now, however we’re beginning to take a look at this as, perhaps we’ve got a handful of households of mannequin antibodies which might be on totally different elements of the spike, protein, totally different areas of the receptor binding area, non-overlapping epitopes that might give us protection,” Hering defined. “So, if the virus zigs, we will zag. If it zags, we will zig.”

Hering stated the annual mannequin for availability of COVID-19 and flu vaccines might function the same mannequin for producing antibodies that maintain tempo with newer variants and any older ones that will re-emerge.

“We’re speaking with regulators now about how that would work, however actually considering by means of that once more, on a yearly foundation, we would offer up to date antibodies that work in opposition to that yr’s variants,” he added.

Since COVID-19 emerged in late 2019, the FDA has granted EUAs to 13 remedies, solely to withdraw 5 of these approvals because the remedies proved unable to fight newer variants of SARS-CoV-2. The withdrawn remedies embrace Regeneron Prescribed drugs’ REGEN-COV mixture (casirivimab and Imdevimab), Eli Lilly’s mixture bamlanivimab and etesevimab, GlaxoSmithKline (GSK)’s sotrovimab, AstraZeneca’s Evusheld, and Lilly’s bebtelovimab.

Of the COVID-19 mAbs available on the market, the bestseller by far is Pfizer’s Paxlovid®, which generated $4.4 billion in revenues within the first 9 months of this yr. However that’s down 74% from the $17 billion Pfizer racked up throughout January-September 2022.

The mAb most just lately granted an EUA for COVID-19 covers a distinct segment inhabitants. InflaRx’s Gohibic (vilobelimab) was licensed in April to deal with COVID-19 in hospitalized adults when initiated inside 48 hours of receiving invasive mechanical air flow (IMV), or extracorporeal membrane oxygenation (ECMO).

Invivyd’s headcount now stands at about 80–90 individuals, Hering stated, in keeping with the 84 full-time staff reported as of February 1 however under the 101 disclosed a yr earlier, in keeping with regulatory filings. Nonetheless, Invivyd plans to develop its employees additional ought to it want extra individuals to commercialize VYD222.

“That’s nonetheless within the planning levels and we’re seeking to see how that each one unfolds,” Hering cautioned. “Definitely, we’re beginning to construct stock to be prepared for a launch, doing the entire totally different market entry and totally different elements that you’d count on in order that we might be prepared for potential launch.”

Does Invivyd envision standing alone in infectious illness, or evolving into the infectious illness subsidiary of some biopharma large?

“Too early to inform proper now,” Hering stated. “We’re very excited for what we’ve achieved to this point, and we’ll actually have a look at that when and if that scenario happens. However proper now, we’re centered on VYD222 and on the point of doubtlessly launch it.”

“Our perception is that COVID-19, sadly, is right here to remain. And yr after yr persons are going to want merchandise like ours—hopefully, fingers crossed—to offer safety and prevention on an ongoing foundation,” Hering added.

Alex Philippidis is senior enterprise editor of GEN.